TG Therapeutics Inc (TGTX) Given Average Rating of “Buy” by Brokerages

TG Therapeutics Inc (NASDAQ:TGTX) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.67.

TGTX has been the subject of a number of analyst reports. BidaskClub downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. HC Wainwright reiterated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, January 22nd. Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 target price on shares of TG Therapeutics in a research note on Wednesday, February 6th. Finally, ValuEngine downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TGTX. Great Point Partners LLC boosted its stake in TG Therapeutics by 53.8% in the fourth quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $12,300,000 after acquiring an additional 1,050,000 shares in the last quarter. Opaleye Management Inc. boosted its stake in TG Therapeutics by 148.4% in the first quarter. Opaleye Management Inc. now owns 1,366,062 shares of the biopharmaceutical company’s stock valued at $10,983,000 after acquiring an additional 816,062 shares in the last quarter. Two Sigma Investments LP boosted its stake in TG Therapeutics by 312.9% in the fourth quarter. Two Sigma Investments LP now owns 769,011 shares of the biopharmaceutical company’s stock valued at $3,153,000 after acquiring an additional 582,771 shares in the last quarter. venBio Select Advisor LLC boosted its stake in TG Therapeutics by 13.1% in the fourth quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after acquiring an additional 549,969 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in TG Therapeutics in the third quarter valued at $1,974,000. Institutional investors own 55.26% of the company’s stock.

Shares of TG Therapeutics stock traded up $0.13 during trading hours on Thursday, reaching $7.15. 38,250 shares of the company were exchanged, compared to its average volume of 2,054,257. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $16.00. The company has a quick ratio of 2.03, a current ratio of 1.72 and a debt-to-equity ratio of 1.89.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, analysts predict that TG Therapeutics will post -1.63 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Read More: What is intrinsic value?

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.